Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omilancor in Moderate to Severe Crohn's Disease
NCT05057273Phase 2Withdrawn
- Sponsor
- NImmune Biopharma
- Start
- Nov 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of omilancor in Crohn's disease, sponsored by NImmune Biopharma. Planned start Nov 2021; status: withdrawn.
02
Drugs
omilancor
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05057273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05057273.